About Dr Fanfan Zhou

Solute Carrier transporters (SLCs) are essential membrane proteins responsible for the cellular influx of various substances including endogenous molecules like hormones and exogenous substrates such as clinically important drugs and toxins. The function of SLCs largely influences therapeutic outcome and toxicity of drugs. The research interest of Dr. Zhou’s team is to investigate the structure-function relationship, molecular regulation and protein-protein interactions of SLCs with an emphasis on how naturally occurring polymorphisms in human transporter genes alter function and affect drug therapies.

Dr. Zhou’s team is a young research group world-widely recognized for their novel findings on SLC transporters. In particular, the in vitro models expressing a range of SLC transporters established in this laboratory have been proved to be an efficient tool in widely screening the interactions of specific drugs/drug candidates with SLC transporters. The research findings of this group significantly contribute to better understanding drug-drug/herb/food interactions and provide important information to therapeutic optimization. This research group is also experienced in investigating how naturally occurring polymorphisms in human transporter genes alter function and affect drug therapies, which information is essential to improve clinical outcome and minimize toxicity of therapies in individuals.

Studies of Dr. Zhou's team have appeared in top journals in the field including Mol Pharmaceu, Br J Pharmacol and AAPS J., which are all highly recognized by international peers. This research team received funding support from the major funding bodies in Australia such as the National Health and Medical Research Council of Australia. Research findings of this group also translated into patents. Post-graduate students and research staff of this team are regularly invited to give oral and poster presentations at national and international conferences. And this research team has established sustainable collaborations with world-leading researchers in Australia and other countries such as US, China and Singapore.

Selected publications

1. Zheng, J, Chan, T, Cheung, F , Zhu, L, Murray, M, Zhou, F. PDZK1 and NHERF1 regulate the function of human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PloS One 2014 Apr 11;9(4):e94712.

2. Xu F, Li Z, Zheng J, Cheung FS, Chan T, Zhu L, Zhuge H and Zhou F. The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential Solute Carrier transporters (SLCs). J Pharm Sci. 2013 Nov;102(11):4205-11.

3. Toh DS, Cheung FS, Murray M, Pern TK, Lee EJ, Zhou F. Functional Analysis of Novel Variants in the Organic Cation/ Ergothioneine Transporter 1 (hOCTN1) identified in Singapore Populations. Mol Pharm. 2013 Jul 1;10(7):2509-16.

4. Cui PH, Rawling T, Gillani TB, Bourget K, Wang XS, Zhou F, Murray M. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochem Pharmacol. 2013 Aug 1;86(3):419-27.

5. Cui PH, Rawling T, Bourget K, Kim T, Duke CC, Doddareddy MR, Hibbs DE, Zhou F, Tattam BN, Petrovic N, Murray M. Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. J Med Chem. 2012 Aug 23;55(16):7163-72.

6. Toh DS, Murray M, Pern Tan K, Mulay V, Grewal T, Lee EJ, Zhou F. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol. 2011 Dec 1;82(11):1692-9.

7. Zhou F, Lee AC, Krafczyk K, Zhu L, Murray M. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol. 2011 Mar;162(6):1380-8.

8. Zhou F, Zhu L, Cui PH, Church WB, Murray M. Functional characterization of the nonsynonymous single nucleotide polymorphisms (SNPs) of the human organic anion transporter 4 (hOAT4). Br J Pharmacol. 2010 Jan 1;159(2):419-27.

9. Cui PH, Lee AC, Zhou F, Murray M. Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in sodium nitroprusside-treated HepG2 cells. Br J Pharmacol. 2010 Apr;159(7):1440-9.

10. Hong M, Li S, Zhou F, Thomas PE, You G. Putative transmembrane domain 12 of the human organic anion transporter hOAT1 determines transporter stability and maturation efficiency. J Pharmacol Exp Ther. 2010 Feb;332(2):650-8.